tbuckley/cabot-search huggingface dataset:
AB1196 NEUROPATHIC PAIN IN GONARTHROSIS: PREVALENCE AND ASSOCIATED FACTORS
Authors: H. Fouzia, F. Z. Taik, I. Berrichi, N. Soba, M. Fourtassi, F. E. Abourazzak
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Pain in knee osteoarthritis remains the main symptomatology, classically considered as nociceptive pain. A neuropathic component of this pain has recently been described. The identification of which is essential for appropriate management. <h3>Objectives</h3> The objective of our study is to evaluate the prevalence of neuropathic pain in patients with knee osteoarthritis, and to identify the associated factors. <h3>Methods</h3> This is a cross-sectional study involving patients with knee osteoarthritis. Sociodemographic and clinical data, including comorbidities, were collected. Neuropathic pain was assessed by the DN4 questionnaire. Neuropathic pain was defined by a DN4 &gt;= 4. Depression, catastrophizing, and central sensitization were assessed by Arabic versions of validated questionnaires, PCS (Pain Catastrophizing Scale) for catastrophizing, and PHQ9 (Patient Health Questionnaire) for depression, CSI (central sensitization inventory) for central sensitization. <h3>Results</h3> 173 patients were included in our study. 88.2% are women. The average age was 58.0±9.19 years. 32.7% had neuropathic pain. VAS mean pain was 4.4±2.1. The median duration of evolution was 3.8 years [1-23]. The average lequesne index was 9.75±3.9. The median of the PCS score was 22 [0 –52], and the median of the PHQ9 score was 7 [0 – 24]. The average CSI score was 38.2±15. 72.6% of patients had comorbidities: 28.8% had obesity and 12.7% were diabetic. In multivariate analysis, only functional disability was associated with the presence of neuropathic pain p=0.04 (OR: 1.19, 95% CI [1.03 – 1.38]. However, pain severity, central sensitization, comorbidities including diabetes and obesity did not come out as associated factors. <h3>Conclusion</h3> Neuropathic pain is quite common in gonarthrosis. Functional disability seems to be an associated factor. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
Molecular Biomarkers for Cardiometabolic Disease: Risk Assessment in Young Individuals
Authors: Usman A. Tahir, Robert E. Gerszten
Journal: Circulation Research (2023)

Cardiometabolic diseases, including cardiovascular disease and diabetes, are major causes of morbidity and mortality worldwide. Despite progress in prevention and treatment, recent trends show a stalling in the reduction of cardiovascular disease morbidity and mortality, paralleled by increasing rates of cardiometabolic disease risk factors in young adults, underscoring the importance of risk assessments in this population. This review highlights the evidence for molecular biomarkers for early risk assessment in young individuals. We examine the utility of traditional biomarkers in young individuals and discuss novel, nontraditional biomarkers specific to pathways contributing to early cardiometabolic disease risk. Additionally, we explore emerging omic technologies and analytical approaches that could enhance risk assessment for cardiometabolic disease.
AB0974 TREATMENT OF AXIAL SPONDYLOARTHRITIS WITH SECUKINUMAB: A REAL-LIFE RETROSPECTIVE COHORT STUDY
Authors: L. Smiljanic Tomicevic, I. Padjen, M. Martinić, M. Mayer, B. Anić
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Data from several large prospective studies have demonstrated that secukinumab is an efficient and safe treatment choice for axial spondyloarthritis (axSpA) <sup>[1]</sup>. <h3>Objectives</h3> The aim of our study was to evaluate data from a real-life cohort of patients with axSpA treated with secukinumab. <h3>Methods</h3> We retrospectively analysed data from our institutional registry of axSpA patients (radiographic and non-radiographic) treated with secukinumab. We analysed the features of patients who continued secukinumab at their last visit and those who discontinued the drug over the follow-up period. We used the Kaplan-Meier curve to estimate the cumulative retention rate of secukinumab. <h3>Results</h3> A total of 57 patients were enrolled in our study. Among them, 26 (45,6%) were women, and 31 (54,4%) were men. The median age was 50 (22-71). There were 26 (45,6%) patients who were bDMARD naïve and 31 (54,4%) patients that had used at least one bDMARD before secukinumab. Among the naïve group, 4 (14,4%) patients discontinued secukinumab, whereas among the group with former bDMARD usage, 12 (38,7%) people discontinued treatment. The ineffectiveness of the drug was the most common reason for discontinuation in both groups. Regarding adverse effects, two people reported respiratory infections. We did not record significant drug safety complications in our cohort. The duration of treatment was 6,5 years. The survival rate of the drug was 91% after six months, 83,4% after 12 months, 75% after 24 months, and 66,6% after 48 months. Table 1 shows detailed clinical aspects of the cohort. <h3>Conclusion</h3> Our data confirmed a good survival rate of secukinumab in patients with axial spondyloarthritis. However, results showed that fewer biologically naïve patients discontinued the secukinumab treatment than those who received the drug after the failure of another biologic. <h3>Reference</h3> [1]Baeten D, Sieper J, Braun J, et al. MEASURE 1 Study Group; MEASURE 2 Study Group. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015 Dec 24;373(26):2534-48. doi: 10.1056/NEJMoa1505066. PMID: 26699169. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Ljiljana Smiljanic Tomicevic Speakers bureau: Novartis, Ely Lilly, Pliva, Pfizer, Abbvie, Ivan Padjen Speakers bureau: Novartis, Ely Lilly, Pliva, Pfizer, Abbvie, Matea Martinić: None declared, Miroslav Mayer Speakers bureau: Novartis, Ely Lilly, Pliva, Pfizer, Abbvie, Branimir Anić Speakers bureau: Novartis, Ely Lilly, Pliva, Pfizer, Abbvie.
AB0092 ANTIBODIES OF THE IMMUNOGLOBULIN G AND A ISOTYPE TO NOVEL PEPTIDES IN EARLY AXIAL SPONDYLOARTHRITIS PATIENTS
Authors: P. Ruytinx, P. Vandormael, D. Quaden, E. Luyten, P. Geusens, J. Vanhoof, A. Agten, F. Vandenabeele, K. De Vlam, V. Somers
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> There is an unmet need for biomarkers to identify patients with axial spondyloarthritis (axSpA), as clinical manifestations often overlap with other disorders. Previously, we identified immunoglobulin G (IgG) antibodies to 3 Hasselt University (UH)-axSpA peptides which could provide a novel tool for diagnosis of a subset of axSpA patients [1]. <h3>Objectives</h3> The aim of this study was to identify novel IgA antibodies in early axSpA patients and to determine their diagnostic potential in combination with previously determined IgG antibodies against UH-axSpA-IgG antigens. <h3>Methods</h3> An axSpA cDNA phage display library constructed from axSpA hip synovium, was used to screen for novel IgA antibodies in plasma from early axSpA patients. The diagnostic value of these antibodies against novel UH-axSpA-IgA and previously identified UH-axSpA-IgG antigens was determined in two independent axSpA cohorts [UH cohort and the Leuven spondyloarthritis biologics cohort (BIOSPAR)], in healthy controls and in patients with chronic low back pain (CLBP) using ELISA. <h3>Results</h3> We identified antibodies to 7 novel UH-axSpA-IgA antigens, of which 6 correspond to non-physiological peptides and 1 to the human histone deacetylase 3 (HDAC3) protein. IgA antibodies against 2 of these 7 novel UH-axSpA-IgA antigens and IgG antibodies against 2 of 3 the previously identified antigens were significantly more present in axSpA patients from the UH cohort (18/70, 25.7%) and the (Bio)SPAR cohort (26/164, 15.9%), compared to controls with CLBP (2/66, 3%). Antibodies to this panel of 4 antigens were present in 21.1 % (30/142) of patients with early axSpA from the UH and (Bio)SPAR cohorts. The positive likelihood ratio for confirming early axSpA using antibodies to these 4 UH-axSpA antigens was 7.0. So far, no clinical correlation between the novel identified IgA antibodies and inflammatory bowel disease could be identified. <h3>Conclusion</h3> Screening an axSpA cDNA phage display library for IgA reactivity resulted in the identification of 7 novel UH-axSpA-IgA antigens, of which 2 show promising biomarker potential for the diagnosis of a subset of axSpA patients, in combination with previously identified UH-axSpA-IgG antigens. <h3>Reference</h3> [1]Quaden D, Vandormael P, Ruytinx P, Geusens P, Corten K, Vanhoof J, et al. Antibodies Against Three Novel Peptides in Early Axial Spondyloarthritis Patients From Two Independent Cohorts. Arthritis Rheumatol. 2020;72(12):2094-105. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0360 IMPACT OF PSYCHOLOGICAL STATUS ON COPING STRATEGIES IN RHEUMATOID ARTHRITIS PATIENTS
Authors: O. Saidane, M. Haddad, S. Bouden, L. Rouached, R. Tekaya, I. Mahmoud, A. Ben Tekaya, L. Abdelmoula
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Objectives</h3> The aim of our study was to determine whether psychological status has an impact on coping strategies in patients with rheumatoid arthritis (RA). <h3>Methods</h3> We conducted a single-centre cross-sectional study for 6 months from 28 March to 28 September 2021 in which we included patients with RA fulfilling the ACR/EULAR 2010 criteria. Characteristics of RA including disease duration and disease activity by the DAS 28 CRP were recorded. The Brief Cope score was used to assess coping strategies. Five grouped coping strategies were evaluated: problem-focused strategies, cognitive restructuring-based strategies, support-based strategies, avoidance-based strategies, and distraction-based strategies. We assessed anxiety and depression using the Hospital Anxiety and Depression Scale (HAD). <h3>Results</h3> Sixty-five patients were included (89.2% women). Mean age was 58.6 ± 9.9 [24-73 years]. Mean duration of RA was 15 ± 10.6 years. Median DAS28 (CRP) was 3.4 (IQR 25-75: 2.8- 4.6) [1.54-6.67]. Median anxiety score was 6 (IQR 25-75: 1-10). Twelve patients (18.5%) had anxiety. Median depression score was 7 (IQR 25-75: 1-13). Eighteen patients had depression (27.7%). Problem-focused and support-based strategies were the most used among all patients, with respective means of 5.6 and 5.5. The association of grouped coping strategies with anxiety and depression was shown in table I. <h3>Conclusion</h3> Among our patients, depression and anxiety decreased the use of cognitive restructuring strategies. However, they were associated with an increase in avoidance-based strategies and problem-focused strategies. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0232 COMPARATIVE FUNCTIONAL ABILITY OF PATIENTS WITH RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AFTER TOTAL KNEE ARTHROPLASTY
Authors: M. Karimov, S. Lapshina, T. Nuriakhmetova, I. Gilmutdinov, A. Nuriakhmetov, S. Ardashev, I. Akhtiamov
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Patients with rheumatoid arthritis (RA) often require adequate disease control prior to total knee arthroplasty (TKA). At the same time, they may have worse outcomes and late complications compared to osteoarthritis (OA) patients. <h3>Objectives</h3> To study the functional abilities of RA patients undergoing TKA compared to OA patients using the KSS scoring system. <h3>Methods</h3> The study included 150 patients: 69 patients (46%) with RA and 81 patients (54%) with OA. 32% of them were males and 68% were females. Th average age of patients with RA was 59.0 [52; 64] years, while in OA group – 66.0 [61; 73] years. Among patients with RA, 60.9% had moderately active diseases and 23.2% had highly active disease prior to intervention. All patients underwent cemented TKA. All of them also completed KSS score prior to surgery, immediately after that and 3 and 12 months after the discharge. Statistical analysis was performed using SPSS version 23.0 (IBM Corp., Armonk, NY, USA). A p value of less than 0.05 was considered statistically significant. <h3>Results</h3> Prior to intervention patients with RA had significantly lower KSS scores compared to OA patients (45.0 [40; 55] versus 60.0 [50; 60], p=0.00, Mann-Whitney). After the surgery KSS became comparable between the two groups (83.0 [74; 84] versus 82.0 [80.5; 85], p=0.754, Mann-Whitney). 3 months after the intervention RA patients had significantly higher KSS scores than prior to surgery (Mdn=88.0, n=69 versus Mdn=40.0, n=69, z=-7.23, p=0.00) or at discharge (Mdn=88.0, n=69 versus Mdn=83.0, n=69, z=-7.25, p=0.00, Wilcoxon test). The same trend was observed for KSS completed 12 months after the surgery (Mdn=93.0, n=69 versus Mdn=88.0 in KSS 3 months after the surgery, n=69, z=-7.26, p=0.00). At the same time, the results of KSS were comparable between RA and OA groups 3 and 12 months after the intervention (88.0 [88; 88] in RA group versus 88.0 [87; 89] in OA group, p=0.772, Mann-Whitney; 94.0 [93; 95] in RA group versus 94.0 [93;95] in OA group, p=0.702, Mann-Whitney, respectively). <h3>Conclusion</h3> The functional abilities of patient with RA after TKA did not differ from those among OA patients regardless of diseases activity despite, despite the fact that among RA patients KSS scores were significantly lower prior to surgery. KSS scores of RA patients improved 3 and 12 months after the intervention and were comparable to OA group. <h3>Reference</h3> [1] Kumagai K, Harigane K, Kusayama Y, Tezuka T, Inaba Y, Saito T. Total knee arthroplasty improves both knee function and disease activity in patients with rheumatoid arthritis. Mod Rheumatol. 2017 Sep;27(5):806-810. doi: 10.1080/14397595.2016.1265705. Epub 2016 Dec 16. PMID: 27919194. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0765 DIFFUSE ALVEOLAR HAEMORRHAGE IS ASSOCIATED WITH HIGH DISEASE ACTIVITY AND HIGH MORTALITY IN AAV PATIENTS: PROSPECTIVE OBSERVATIONAL STUDY
Authors: A. Sharma, G. Naidu, P. Deo, J. Samanta, R. Nada, K. Sharma, V. Dhir, R. Minz, S. Jain
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Diffuse alveolar haemorrhage (DAH) is a life-threatening emergency in patients with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitides (AAV). <h3>Objectives</h3> To describe the clinical features and outcomes of AAV patients with DAH and compare them with non-DAH AAV patients. <h3>Methods</h3> Observational cohort study based on the prospective Indian Vasculitis Registry. 292 AAV patients were included in the study. DAH was diagnosed based on the clinical features and radiology findings. Fischer's exact test and Mann-Whitney U test were used for comparison. A p value of &lt;0.05 was considered as significant. <h3>Results</h3> Fifty (17%) patients had DAH. Median age was 40.5 years and males constituted 54%. GPA, MPA and EGPA were the diagnoses in 39, 10 and 1 patients, respectively. Prevalence of DAH was higher in MPA (37.05%) than GPA (15.5%; p=0.0132). Haemoptysis was present in only 70% of patients while cough (76%) and breathlessness (62%) were the other respiratory symptoms. Six (12%) patients did not have any of these clinical features and were diagnosed with DAH based on radiology. DAH patients had more renal involvement (82% vs 38.4%; p&lt;0.00001), less ocular involvement (34% vs 52.9%; p=0.0193) and hearing loss (20% vs 39.7%; p=0.0094) and higher BVASv3 score at presentation (21.6 vs 15.4; p=0.00026). Table 1 and Figure 1 shows the comparison of clinical features between the two groups. Remission induction agents used were glucocorticoids (100%), cyclophosphamide (62%) and rituximab (38%). PLEX was used in only 5 (10%) patients. Eleven (22%) patients died during follow up compared to 17 (7%) in patients without DAH (p=0.0028). <h3>Conclusion</h3> Presence of DAH in AAV patients was associated with high disease activity and higher mortality on follow up. Haemoptysis may be absent in a significant number of patients with DAH and hence, high index of suspicion is required to suspect and diagnose it early. * p &lt; 0.05 <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0567 SEXUAL DYSFUNCTION IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Authors: M. H. Fernandes Lourenco, R. Pinheiro Torres, S. Rodrigues-Manica, V. Fraga, C. Abreu, R. Costa, C. Matos, B. Mendes, B. Samões, I. Silva, F. M. Pimentel-Santos, M. Costa, J. Branco, A. Sepriano
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Due to its multisystemic involvement, systemic lupus erythematosus (SLE) can have a significant impact on patients' quality of life (QoL). Sexual (dis)function is a key component of QoL but is often underappreciated. Little is known about sexual disfunction in SLE patients, a condition that primarily affects women during their fertile age. <h3>Objectives</h3> We aimed at determining the prevalence of sexual dysfunction among women with SLE and predictors thereof. <h3>Methods</h3> We performed a cross-sectional multicenter study in which women (18-70 years-old) with a clinical diagnosis of SLE (according to their treating rheumatologist) were included. An anonymous online questionnaire was perfomed where data on demographics (e.g., age), symptoms of depression and anxiety [Hospital Anxiety and Depression Scale (HADS)), health-related QoL (Short Form Health Survey Index 36 Item (SF36)]) and sexual function [Female Sexual Function Index (FSFI) - a 19-item patient-report outcome that assesses female sexual function]) were collected. Data on clinical features [disease activity according to the Safety of Estrogens in Lupus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI), organ involvement and evaluation of comorbidity (Charlson Comorbidity Index)] and on treatment status were collected from medical records. The main outcome was sexual dysfunction, defined as FSFI&lt;26.5 (validated cut-off). A multivariable logistic regression was perfomed to test the association of clinical and demographic characteristics with sexual dysfunction (present vs absent). <h3>Results</h3> In total, 194 female patients with SLE were included (mean age 44 years-old [standard deviation (SD) 11]). The mean SELENA-SLEDAI score was 1.7 (SD: 2.2), corresponding to low disease activity, and 94% of patients were on classical disease-modifying antirheumatic drugs. The mean value of HADS was 9 (0-21), for both depression and anxiety scores. Regarding SF36, the mental component had a mean value of 61 (0-100) and the physical one of 70 (0-100). Sexual disfunction was present in 128 (66%) patients. In the multivariable analysis (Table 1), older age (OR: 1.04; 95%CI: 1.01; 1.07), higher SELENA-SLEDAI (OR: 1.18; 95%CI: 1.01; 1.40), higher HADS depression score (OR: 1.20; 95%CI: 1.01; 1.43), as well as a lower (that is, worse) SF36 mental component score (OR: 0.97; 95%CI: 0.95; 0.98) were independently associated with sexual dysfunction. <h3>Conclusion</h3> Sexual disfunction is common in women with SLE and is influenced by both physical and mental health components. Clinicians should consider both for the optimal management of their patients in order to improve their sexual QoL. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0799 ASSOCIATION BETWEEN MUSCLE QUALITY AND MORTALITY IN PATIENTS WITH ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Authors: J. W. Ha, S. S. Ahn, Y. Park, S. Lee
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Decreased muscle mass is frequently observed in patients with autoimmune rheumatic diseases; however, the relationship between muscle quality and patient outcomes has not been well understood. <h3>Objectives</h3> This study evaluated the influence of muscle quality on the outcomes of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). <h3>Methods</h3> Records of patients with AAV (microscopic polyangiitis, granulomatosis with polyangiitis, and eosinophilic granulomatosis with polyangiitis) at the Severance Hospital having computed tomography (CT) images at disease diagnosis were retrospectively reviewed. For muscle quality measures, normal attenuation muscle area (NAMA), low attenuation muscle area (LAMA), total abdominal muscle area (TAMA), and intramuscular adipose tissue (IMAT) in the axial muscles of the middle third lumbar vertebra level was calculated. Correlations between NAMA, LAMA, and IMAT and patient characteristics and outcomes were assessed. <h3>Results</h3> A total of 136 patients with CT images at AAV diagnosis were identified. Correlation analyses revealed that age, female sex, total cholesterol, and alanine aminotransferase were significantly associated with NAMA. LAMA was associated with age, body mass index (BMI), five-factor score (FFS), and C-reactive protein, while a relationship between IMAT and age and BMI was observed. Cox-proportional hazard analysis demonstrated that NAMA/TAMA≤0.46 (odds ratio [OR] 5.612, 95% confidence interval [CI] 1.758-17.909, p=0.004), female sex (OR 0.228, 95% CI 0.075, 0.684, p=0.008), dyslipidemia (OR 3.819, 95% CI 1.380, 10.571, p=0.010), and FFS (OR 2.160, 1.298-3.595, p=0.003), were independent factors associated with mortality. <h3>Conclusion</h3> Higher mortality was observed in patients with AAV with NAMA/TAMA ≤ 0.46, indicating that cautious monitoring is required in these patients. <h3>References</h3> [1]An HJ, Tizaoui K, Terrazzino S et al (2020) Sarcopenia in Autoimmune and Rheumatic Diseases: A Comprehensive Review. Int J Mol Sci 2020;21. https://doi.org/10.3390/ijms21165678 [2]Lee MJ, Kim HK, Kim EH, Bae SJ, Kim KW, Kim MJ, Choe J (2021) Association Between Muscle Quality Measured by Abdominal Computed Tomography and Subclinical Coronary Atherosclerosis. Arterioscler Thromb Vasc Biol 2021;41:e128-e140. https://doi.org/10.1161/atvbaha.120.315054 <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.